Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study by Jun Guo et al.
Guo et al. BMC Cancer 2013, 13:136
http://www.biomedcentral.com/1471-2407/13/136RESEARCH ARTICLE Open AccessSafety and efficacy of everolimus in Chinese
patients with metastatic renal cell carcinoma
resistant to vascular endothelial growth factor
receptor-tyrosine kinase inhibitor therapy: an
open-label phase 1b study
Jun Guo1*, Yiran Huang2, Xu Zhang3, Fangjian Zhou4, Yinghao Sun5, Shukui Qin6, Zhangqun Ye7, Hui Wang8,
Annette Jappe9, Patrick Straub10, Nicoletta Pirotta11 and Sven Gogov12Abstract
Background: In China, there are currently no approved therapies for the treatment of metastatic renal cell
carcinoma (mRCC) following progression with vascular endothelial growth factor (VEGF)-targeted agents. In the
phase 3 RECORD-1 trial, the mammalian target of rapamycin (mTOR) inhibitor everolimus afforded clinical benefit
with good tolerability in Western patients with mRCC whose disease had progressed despite VEGF receptor-tyrosine
kinase inhibitor (VEGFr-TKI) therapy. This phase 1b study was designed to further evaluate the safety and efficacy of
everolimus in VEGFr-TKI-refractory Chinese patients with mRCC.
Methods: An open-label, multicenter phase 1b study enrolled Chinese patients with mRCC who were intolerant to,
or progressed on, previous VEGFr-TKI therapy (N = 64). Patients received everolimus 10 mg daily until objective
tumor progression (according to RECIST, version 1.0), unacceptable toxicity, death, or study discontinuation for any
other reason. The final data analysis cut-off date was November 30, 2011.
Results: A total of 64 patients were included in the study. Median age was 52 years (range, 19–75 years) and 69%
of patients were male. Median duration of everolimus therapy was 4.1 months (range, 0.0-16.1 months). Expected
known class-effect toxicities related to mTOR inhibitor therapy were observed, including anemia (64%),
hypertriglyceridemia (55%), mouth ulceration (53%), hyperglycemia (52%), hypercholesterolemia (50%), and
pulmonary events (31%). Common grade 3/4 adverse events were anemia (20%), hyperglycemia (13%), increased
gamma-glutamyltransferase (11%), hyponatremia (8%), dyspnea (8%), hypertriglyceridemia (6%), and lymphopenia
(6%). Median PFS was 6.9 months (95% CI, 3.7-12.5 months) and the overall tumor response rate was 5%
(95% CI, 1-13%). The majority of patients (61%) had stable disease as their best overall tumor response.
Conclusions: Safety and efficacy results were comparable to those of the RECORD-1 trial. Everolimus is generally
well tolerated and provides clinical benefit to Chinese patients with anti-VEGF-refractory mRCC.
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Renal cell carcinoma (RCC), the most common form of
kidney tumor, accounts for up to 92% of all cases of kid-
ney cancer [1]. In the United States alone, an estimated
64,770 new cases of renal tumors are expected to be diag-
nosed during 2012, which will ultimately attribute to
13,570 deaths [1]. The incidence of kidney cancer in China
is low, compared with the average global incidence rate
(2.1 vs 4.0 per 100,000) [2]. However, the incidence of and
death rate from kidney cancer in China has risen during
recent years [3].
Surgery forms the primary standard of care for most
localized kidney cancers [1]. However, one third of
patients who undergo surgery for localized disease will
experience recurrence and approximately a quarter of
patients have locally invasive or metastatic RCC (mRCC)
at the time of diagnosis [4]. In such settings, targeted
agents have been shown to afford significant clinical
benefit with acceptable safety [5-11]. The vascular endo-
thelial growth factor receptor-tyrosine kinase inhibitors
(VEGFr-TKIs) sunitinib and sorafenib are approved in
China for first-line treatment of patients with mRCC.
Sequential lines of therapy are typically required to
maintain clinical benefit in patients with mRCC. Clinical
practice guidelines in the United States and Europe
recommend targeted agents or cytokines for first- and
subsequent-line treatment of patients with mRCC [12-15].
VEGF-targeted agents are recommended as first-line ther-
apy for the majority of patients (those who are at low or
intermediate risk). Everolimus is recommended for pa-
tients who fail initial VEGFr-TKI therapy and axitinib for
patients who fail previous systemic therapy. Although
there are currently no approved therapies in China for the
treatment of patients with mRCC refractory to VEGFr-
TKIs, local clinical practice guidelines recommend evero-
limus for this patient population.
The PI3K/AKT/mTOR pathway is dysregulated in many
cancers, including RCC [16]. mTOR is a serine/threonine
kinase that binds specifically to the FK506 binding protein
12 (FKBP12)-rapamycin complex [17]. mTOR is activated
by components of the PI3K pathway and tuberous sclerosis
complex (TSC) and regulates protein synthesis required
for cell growth and proliferation, metabolism, and angio-
genesis [18]. Overactivation of mTOR signaling occurs via
a number of mechanisms, including overexpression or
activation of growth factor receptors, activating mutations
in PI3K/AKT, or decreased expression of TSC [18]. Over-
production of VEGF and other growth factors in tumor
cells leads to activation of mTOR signaling in neighboring
endothelial cells, thereby increasing angiogenesis [18]. In-
hibition of mTOR signaling results in decreased cell
growth and proliferation, cellular metabolism, and angio-
genesis, ultimately leading to cell cycle block at the G1
phase [19]. The mTOR inhibitor everolimus binds to theintracellular protein FKBP-12, forming a complex that in-
hibits the mTOR serine-threonine kinase [19].
Everolimus has been evaluated in patients with cancer
in multiple clinical studies. Phase 1 PK/PD studies dem-
onstrated that continuous daily dosing with everolimus
10 mg resulted in a more profound and sustained inhib-
ition of mTOR than that achieved with a weekly dosage
schedule [20,21]. Anti-tumor activity of everolimus 10 mg
daily was shown in a phase 2 trial of patients with mRCC
[22,23], and results of the phase 3 RECORD-1 study
demonstrated a progression-free survival (PFS) benefit of
everolimus 10 mg daily over placebo in patients with
VEGFr-TKI–refractory mRCC (4.9 vs 1.9 months; HR 0.33;
95% CI, 0.25-0.43; P < .001) [10]. In addition, pharmacody-
namic modeling of tumor growth in patients enrolled in
RECORD-1 demonstrated that everolimus 5 mg daily and
10 mg daily significantly slowed the growth of mRCC tar-
get lesions, non-target lesions, and new metastases com-
pared with placebo (P < .001) [24,25].
A phase 1 study in Chinese patients with advanced
solid tumors (N = 24), including mRCC (n = 6), was
conducted to specifically evaluate the efficacy and safety
of everolimus in a Chinese population [26]. Results dem-
onstrated that everolimus doses of 5 mg and 10 mg daily
were well tolerated, and 67% of patients experienced
stable disease as their best overall tumor response [26].
Median duration of everolimus exposure for patients
with mRCC was 26.4 weeks (6.1 months). Herein, we re-
port results of a larger study of everolimus in Chinese
patients with mRCC.
Methods
Study design and treatment
In this open-label, multicenter phase 1b study, patients
received everolimus 10 mg (2 × 5-mg tablets) daily until
objective tumor progression (according to RECIST,
version 1.0), unacceptable toxicity, death, or study dis-
continuation for any other reason. If a patient experi-
enced unacceptable toxicity, dose reductions to 5 mg
daily or 5 mg every other day or dose interruptions were
permitted. This study was conducted according to the
ethical principles of the Declaration of Helsinki. The
study protocol was reviewed and approved by the Inde-
pendent Ethics Committee or Institutional Review Board
for each participating study center in China. Written in-
formed consent was obtained from each patient before
screening procedures were initiated.
Primary end points were safety and tolerability. Second-
ary end points included disease control rate (DCR, defined
as the proportion of patients with a best overall tumor re-
sponse of complete response [CR], partial response [PR],
or stable disease [SD]), overall response rate (ORR: CR +
PR), PFS, and overall survival (OS). Additional exploratory
outcomes included the evaluation of systemic pre-dose
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pre-dose exposure and predefined safety/efficacy end points.
Patients
Adult Chinese patients with mRCC who were intolerant
to or who progressed while still on or after stopping
treatment with VEGFr-TKI therapy within 6 months
were enrolled (N = 64). Patients were required to have
confirmed clear cell mRCC with at least 1 measurable
lesion (RECIST, version 1.0), a Karnofsky Performance
Status (KPS) ≥ 70%, and adequate bone marrow, liver,
and renal function. Patients with brain metastases were
eligible if they were neurologically stable and did not re-
quire corticosteroids. Patients were ineligible if they had
received previous chemotherapy, immunotherapy, radio-
therapy, or an investigational agent (at the time of study
protocol preparation, pazopanib and axitinib were in-
cluded) within 4 weeks of study entry or sunitinib and/
or sorafenib within 2 weeks of first everolimus dose.
Previous treatment with mTOR inhibitors was not per-
mitted. Patients who had received chronic treatment with
immunosuppressive agents were ineligible for the study,
whereas low-dose corticosteroids were permitted. Patients
with severe and/or uncontrolled medical conditions in-
cluding unstable angina, congestive heart failure, uncon-
trolled hypercholesterolemia, or diabetes were ineligible.
Assessments and statistical methods
Safety assessments included the occurrence of adverse
events (AEs), serious AEs (SAEs), and monitoring of he-
matology, biochemistry, serum lipid profile, and vital
signs. AE monitoring continued for 4 weeks after patients
received their last dose of study drug. The safety popula-
tion was defined as all patients who received ≥ 1 dose of
everolimus and had ≥ 1 postbaseline safety assessment.
The frequency distribution of patients with AEs and la-
boratory data abnormalities were summarized by worst
CTC grade based on Common Terminology Criteria for
Adverse Events (CTCAE) v 3.0 [27]. The estimated raw
incidence (95% CI) of grade 3–4 AEs and of SAEs was
identified as the primary safety analysis. Pulmonary events
were diagnosed by the participating investigators and not
confirmed independently. Kaplan-Meier estimates evalu-
ated the time to onset of non-infectious pneumonitis.
For efficacy evaluation, CT/MRI scans and/or bone
scan if bone metastases were present or suspected were
carried out at baseline and every 8 weeks for the first
year of treatment, then every 12 weeks and at treatment
discontinuation. Assessment of overall lesion response
was performed per RECIST criteria (version 1.0), and
radiologic information was reviewed and evaluated by
the investigator and/or local radiologists. The efficacy
population comprised all patients who received ≥ 1 dose
of everolimus. Efficacy end points included DCR, ORR,PFS, and OS. The Kaplan-Meier method was used to
analyze time to event end points (PFS and OS). PFS was
defined as the time from the start of treatment to the
date of documented tumor progression or death due to
any cause, whichever came first. In the absence of a PFS
event, patients were censored at the time of their last
valid tumor assessment. OS was defined as the time
from treatment start to death due to any cause; patients
lost to follow-up or who were still alive at analysis cut-
off date were censored at their last contact date. The
final data analysis cut-off date was November 30, 2011.
For PK assessments, pre-dose PK samples were collected
on day 1 of cycles 2 and 4 by direct venipuncture into poly-
propylene tubes containing K2 ethylene diamine tetraacetic
acid. Patients were then instructed to take everolimus after
the pre-dose sample had been collected, so that an accurate
trough level could be determined. Everolimus concentra-
tions in whole blood were determined by a liquid chroma-
tography tandem mass spectrometry method after a solid
phase extraction. The lower limit of quantitation was
0.3 ng/mL. Pre-dose trough samples (Cmin) collected at
cycle 2 day 1 and cycle 4 day 1 could represent the mini-
mum everolimus exposure under steady-state conditions. A
linear mixed model analysis of log-transformed steady-state
pre-dose minimum plasma concentrations (Cmin) normal-
ized to the dose of 10 mg/day, including the cycle as fixed
effect and the patient as random effect, overall mean, 90%
CI, and inter- and intra-patient variability, were estimated.
Exploratory analyses of the relationship between log-
transformed, time-normalized everolimus concentration
and time to occurrence of pre-selected safety/efficacy end
points were performed using the Cox regression model.
The sample size was identified as the minimum num-
ber of patients required to assess everolimus-related tox-
icities in the studied population and was not based on
formal calculation. The study included a preplanned in-
terim analysis of safety, which was conducted 4 months
after treatment initiation by the last patient enrolled,
and a final analysis after 12 months of treatment. All pa-
tients still receiving everolimus at the time of the final
analysis were given the option to continue treatment
until disease progression or unacceptable toxicity.
Results
Patient disposition
At the time of the final analysis, 54 patients (84%) had
discontinued treatment. The most frequent reasons for
discontinuation included disease progression (n = 26,
41%), AEs (n = 15, 23%), withdrawal of consent (n = 6,
9%), and death (n = 3, 5%).
Demographics and baseline characteristics
The full analysis set comprised 64 patients who received ≥
1 dose of everolimus 10 mg/day (Table 1). The majority of
Table 1 Patient demographics and baseline disease
characteristics
Characteristic Everolimus 10 mg/day
N = 64









All previous systemic therapy, n (%)
Immunotherapy 29 (45)
Chemotherapy 6 (9)
Targeted therapy 64 (100)
Other 10 (16)
Previous surgery, n (%) 64 (100)
Previous radiotherapy, n (%) 17 (27)








Pleural effusion (malignant) 11 (17)
Retroperitoneal mass 9 (14)
Mediastinum 8 (13)
Thoracic lymph nodes 7 (11)
VEGFr-TKI, vascular endothelial growth factor receptor-tyrosine
kinase inhibitor.
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Chinese ethnicity. Median age was 52 years and most pa-
tients were < 65 years of age (n = 58, 91%). Most patients
presented with histologically or cytologically confirmed
clear-cell adenocarcinoma of the kidneys (n = 62, 97%)
and the majority (n = 41, 64%) had a time since initial
diagnosis ≥ 24 months. Twenty-six patients (41%) had
metastatic involvement of ≥ 3 organs, and the lungs were
the most common site of metastasis (n = 52, 81%). All pa-
tients had undergone surgery and received previous
VEGFr-TKI therapy, with half the population receiving
previous sorafenib.
Treatment exposure
Median duration of everolimus therapy was 4.1 months
(range, 0.0-16.1 months). The mean cumulative dose was
1616.88 mg, with a mean dose intensity of 8.95 mg/day(median, 9.90 mg/day), corresponding to a mean relative
dose intensity of 0.89 (median, 0.99). The majority of
patients (n = 45, 70%) had a relative dose intensity be-
tween 0.90 and < 1.10. Overall, 37 patients (58%) required
≥ 1 dose reduction/interruption of everolimus: 14 patients
(22%) had their dose reduced/interrupted once, and 23
patients (36%) required dose reductions/interruptions
more than once over the course of the study. The most
common reason for dose reduction/interruption was man-
agement of AEs (n = 24, 38%).
Safety
Seven patients died within 28 days of treatment discon-
tinuation. The principal cause of death was progressive
disease in 5 patients; 1 patient died of respiratory failure
suspected to be study drug-related, and 1 patient died of
multi-organ failure not suspected to be study drug-
related.
A total of 27 patients (42%, 95% CI, 30-55%) reported ≥
1 on-treatment SAE. The most common SAEs occurring
in ≥ 3% of patients included dyspnea (9%), pyrexia (6%),
lung infection (3%), anemia (3%), multi-organ failure (3%),
respiratory failure (3%), and renal failure (3%). SAEs were
suspected to be treatment related in 11 patients (17%).
Treatment-related SAEs occurring in ≥ 3% of patients
were pyrexia (5%) and anemia (3%).
AEs regardless of relationship to study drug were
reported in 62 patients (97%). The most frequently oc-
curring AEs were anemia (64%), hypertriglyceridemia
(55%), mouth ulceration (53%), hyperglycemia (52%),
hypercholesterolemia (50%), pyrexia (41%), increased
lactate dehydrogenase (38%), fatigue (31%), increased
gamma-glutamyltransferase (GGT, 31%), and rash (31%)
(Table 2). A total of 48 patients (75%, 95% CI, 63-85%)
experienced at least one grade 3 or 4 AE regardless of
relationship to study drug. Common grade 3/4 AEs were
anemia (20%), hyperglycemia (13%), increased GGT
(11%), hyponatremia (8%), dyspnea (8%), hypertriglyc-
eridemia (6%), and lymphopenia (6%).
Non-infectious pneumonitis events were reported in
20 patients (31%) and included interstitial lung disease
(n = 14, 22%), pneumonitis (n = 5, 8%), and pulmonary
fibrosis (n = 1, 2%). Grade 3 non-infectious pneumonitis
was reported in 4 patients (6%), all of whom had lung
metastases at study entry: 3 events improved to grade 1/
2 after steroid therapy, oxygen inhalation, and/or dose
adjustment; 1 event of pulmonary fibrosis improved to
grade 2 following discontinuation of everolimus. Overall,
no grade 4 non-infectious pneumonitis was reported.
The probability of onset of non-infectious pneumonitis
was estimated to be 6% (95% CI, 3-16%) at 1 month and
32% (95% CI, 21- 46%) at 4 months. The median time to
first occurrence of non-infectious pneumonitis was not
reached.
Table 2 All-grade AEs occurring in ≥ 10% of patients and corresponding grades 3 and 4 AEs
Everolimus 10 mg/day (n = 64)
AE, n (%) All-grade Grade 3 Grade 4
Anemia 41 (64) 10 (16) 3 (5)
Hypertriglyceridemia 35 (55) 4 (6) 0 (0)
Mouth ulceration 34 (53) 2 (3) 0 (0)
Hyperglycemia 33 (52) 8 (13) 0 (0)
Hypercholesterolemia 32 (50) 0 (0) 0 (0)
Pyrexia 26 (41) 1 (2) 0 (0)
Increased blood lactate dehydrogenase 24 (38) 1 (2) 1 (2)
Fatigue 20 (31) 1 (2) 0 (0)
Increased gamma-glutamyltransferase 20 (31) 7 (11) 0 (0)
Rash 20 (31) 0 (0) 0 (0)
Increased blood creatinine 19 (30) 0 (0) 1 (2)
Cough 18 (28) 0 (0) 0 (0)
Increased aspartate aminotransferase 17 (27) 0 (0) 0 (0)
Increased alanine aminotransferase 15 (23) 1 (2) 0 (0)
Epistaxis 15 (23) 1 (2) 0 (0)
Hypocalcemia 14 (22) 0 (0) 0 (0)
Interstitial lung disease 14 (22) 1 (2) 0 (0)
Leukopenia 14 (22) 0 (0) 0 (0)
Pruritus 14 (22) 0 (0) 0 (0)
Peripheral edema 13 (20) 2 (3) 0 (0)
Decreased platelet count 13 (20) 1 (2) 0 (0)
Diarrhea 12 (19) 1 (2) 0 (0)
Dyspnea 12 (19) 1 (2) 4 (6)
Increased blood alkaline phosphatase 11 (17) 1 (2) 0 (0)
Hypokalemia 11 (17) 0 (0) 3 (5)
Lymphopenia 10 (16) 4 (6) 0 (0)
Nasopharyngitis 9 (14) 0 (0) 0 (0)
Dizziness 8 (13) 0 (0) 0 (0)
Insomnia 8 (13) 0 (0) 0 (0)
Increased blood creatine phosphokinase 7 (11) 0 (0) 0 (0)
Decreased appetite 7 (11) 1 (2) 0 (0)
Decreased hemoglobin 7 (11) 2 (3) 0 (0)
Hyponatremia 7 (11) 5 (8) 0 (0)
Nausea 7 (11) 0 (0) 0 (0)
Upper respiratory tract infection 7 (11) 0 (0) 0 (0)
Increased white blood cell count 7 (11) 0 (0) 0 (0)
AE, adverse event.
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were decreased hemoglobin (80%), increased triglycer-
ides (77%), increased fasting glucose (72%), increased
cholesterol (61%), and decreased absolute lymphocyte
count (61%). Common grade 3/4 laboratory abnormal-
ities included decreased hemoglobin (23%), decreased
absolute lymphocytes (20%), and increased GGT (16%).Efficacy
At the data cut-off date, median PFS was estimated to
be 6.9 months (95% CI, 3.7-12.5 months, Table 3 and
Figure 1). The estimated probability of PFS was 62%
(95% CI, 47-73%) at 4 months, 52% (95% CI, 38-64%) at
6 months, and 36% (95% CI, 22-51%) at 12 months.
Median OS was not reached (Figure 2). The estimated
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and 56% (95% CI, 42-68%) at 12 months.
Confirmed objective tumor responses (all PRs) evaluated
by investigator assessment were seen in 3 patients, corre-
sponding to an ORR of 5% (95% CI, 1-13%, Table 3). Stable
disease was reported in 39 patients (61%). Everolimus ther-
apy in this patient population was associated with a DCR
of 66% (95% CI, 53-77%).
Pharmacokinetics
Mean Cmin after administration of everolimus 10 mg/day
was 21.4 ± 12.4 ng/mL at cycle 2, day 1 (n = 36) and 15.0 ±
9.97 ng/mL at cycle 4, day 1 (n = 22). Mean Cmin after ad-
ministration of everolimus 5 mg/day was 0.7 ng/mL at
cycle 2, day 1 (n = 1) and 8.8 ± 1.14 ng/mL at cycle 4, day 1
(n = 3). Mean Cmin at cycle 4, day 1 at the 10-mg/day dose
was approximately twice the mean Cmin value at the 5-mg
/day dose, which confirms a dose-proportional increase in
pre-dose exposure of everolimus after daily administration.
In the analysis of PFS, the estimated risk ratio of 0.67
suggested a trend toward longer PFS with higher time-
normalized everolimus Cmin. However, the corresponding
95% CI (0.273-1.668) included unity, thereby precluding
conclusion of any statistically significant relationship. ThereTable 3 Summary of efficacy measures
Everolimus
10 mg/day, N = 64
PFS
PFS events, n (%) 35 (55)
Progression 26 (41)
Death 9 (14)
Censored observations, n (%) 29 (45)
Median PFS, months (95% CI) 6.9 (3.7-12.5)
Best Overall Response, n (%)
Complete response 0
Partial response 3 (5)
Stable disease 39 (61)
Progressive disease 8 (13)
Unknown* 14 (22)
Response analysis, n (%)
ORR (CR or PR) 3 (5)
[95% CI for ORR] [1-13]
DCR (CR or PR or SD) 42 (66)
[95% CI for DCR] [53–77]
OS
Median OS, months (95% CI) NR (10.7-NR)
Probability of OS at 6 months,% (95% CI) 76 (64–85)
Probability of OS at 12 months,% (95% CI) 56 (42–68)
*Includes patients with no tumor assessments.
PFS, progression-free survival; ORR, overall response rate; OS, overall survival;
CR, complete response; PR, partial response, SD, stable disease; NR,
not reached.was no apparent difference between patients in the evero-
limus time-normalized Cmin categories of < 10 ng/mL, 10–
25 ng/mL, and > 25 ng/mL and all grades of non-infectious
pneumonitis and stomatitis/oral mucositis.
Discussion
This phase 1b study was planned and conducted to
evaluate the safety and efficacy profile of everolimus in
Chinese patients with mRCC after failure of VEGFr-TKI
therapy. Overall safety findings from this study were
consistent with those reported in the phase 3 RECORD-
1 study [10,28] and with a phase 1 study conducted in
Chinese patients with advanced solid tumors [26]. In
RECORD-1, everolimus 10 mg daily was generally well
tolerated in patients with mRCC whose disease had
progressed despite previous VEGFr-TKI therapy. Com-
mon AEs reported in patients treated with everolimus
included stomatitis, infections, asthenia, fatigue, and
diarrhea; common laboratory abnormalities included de-
creased hemoglobin, increased glucose, and increased
cholesterol and triglycerides; pneumonitis occurred in
14% of patients (grade 3, 4%; grade 4, 0%) [10,28]. A
phase 1 study investigated everolimus 5 mg and 10 mg
daily in Chinese patients with different tumor types
(breast cancer, non-small cell lung cancer, RCC, and gas-
tric cancer), results of which confirmed the safety of
everolimus in Chinese patients. Most AEs were grade 1
or 2, and the most common (all grades) were hypergly-
cemia, fatigue, and anemia [26]. Based on clinical results,
guidelines for the appropriate management of AEs related
to everolimus treatment have been developed [29,30].
In this study, expected known class-effect toxicities re-
lated to mTOR inhibitor therapy were observed, including
anemia, hypertriglyceridemia, hyperglycemia, hypercholes-
terolemia, pulmonary events, and stomatitis. Most of the
AEs were grade 1/2 in severity. Although anemia occurred
in 64% of the patients, only 16% and 5% of patients experi-
enced grade 3 or 4 events, respectively. It is important to
note that a large portion of the study population had
abnormal hematologic values at baseline, including grades
1–2 decreased hemoglobin in 52% of patients. Many pa-
tients also had abnormal biochemistry values at baseline,
including 44% with increased triglycerides (grades 1–2)
and 28% with increased glucose (grades 1–2). Non-
infectious pneumonitis events (interstitial lung disease,
pneumonitis, and pulmonary fibrosis) occurred in 31% of
patients in this study. Although this percentage was higher
than in the overall RECORD-1 population based on
blinded investigator assessment (14%) [10], it was similar
to the incidence reported based on prospective, blinded
independent review of CT scans from patients in the
RECORD-1 trial in whom a diagnosis of clinical pneu-
monitis was not made but who experienced radio-



















0 2 4 6 8 10 12 14 16
Time, months
Censoring Times
everolimus (n/N = 35/64)
Kaplan-Meir median
everolimus: 6.93 months
No. of patients still at risk
everolimus 64 45 31 23 17 15 8 1 0
Figure 1 Kaplan-Meier estimate of progression-free survival. The plot depicts the probability of progression-free survival over time (months)
for patients who received everolimus (full analysis set population). The square symbol represents censoring times. The number of patients still at
risk is shown for each time point.
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incidence of noninfectious pneumonitis reported in the
Japanese subpopulation of RECORD-1 (27%) [32]. In the
current study, most pulmonary events were grade 1 or 2;
only 6% of patients experienced a grade 3 pulmonary
event. In the overall population of RECORD-1, 4% of pa-
tients experienced a grade 3 pulmonary event and there
were no grade 4 events; in the Japanese subpopulation of
RECORD-1 there were no grade 3 events [10,32].
Efficacy outcomes in this study are comparable to
those from RECORD-1 [10]. The confirmed objective
tumor response rate (all PRs) was 5% in this study versus
1.8% in RECORD-1 [10]. DCR was 66%, which was also
comparable to the 69% of patients who achieved PR or
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Figure 2 Kaplan-Meier estimate of overall survival. The plot depicts the
received everolimus. The square symbol represents censoring times. The nudaily provided clinical benefit to patients with mRCC
whose disease had progressed despite VEGFr-TKI ther-
apy (median PFS, 4.9 months vs 1.9 months for placebo;
HR 0.33, P < .001). In comparison, the median PFS asso-
ciated with everolimus in Chinese patients refractory to
previous VEGFr-TKI therapy in this single-arm study
was 6.9 months.
Conclusions
Everolimus provides clinical benefit to Chinese patients
with mRCC, with comparable efficacy to that observed
in Western patients. Everolimus was generally well toler-
ated and safety findings were consistent with those from
RECORD-1 and from a phase 1 study of everolimus in
Chinese patients with advanced solid tumors. This study10 12 14 18
e, months
16
37 18 8 01
probability of overall survival over time (months) for patients who
mber of patients still at risk is shown for each time point.
Guo et al. BMC Cancer 2013, 13:136 Page 8 of 9
http://www.biomedcentral.com/1471-2407/13/136provides further evidence supporting the use of everolimus
as a standard of care in patients with VEGFr-TKI–refractory
mRCC.
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